Hir­ing? How End­points can help your com­pa­ny fill open po­si­tions with our tal­ent­ed read­ers

We’ve just launched End­points Ca­reers, our new prod­uct con­nect­ing em­ploy­ers and job­seek­ers. The com­pe­ti­tion for bio­phar­ma tal­ent is fierce, and giv­en the unique place End­points News has in the in­dus­try, we think our ap­proach has a few key ad­van­tages that make this a com­pelling of­fer and not just an­oth­er “job board.”

The first rea­son is that we’re an­chor­ing it to En­ter­prise, our $1,000/year paid sub­scrip­tion plan for com­pa­nies of all sizes. You can think of En­ter­prise as the “com­plete” ver­sion of End­points News. No mat­ter how large or small the com­pa­ny is, that one price un­locks pay­wall con­tent for every em­ploy­ee. No seat li­cens­es or vol­ume pric­ing. We want to make this pro­gram an easy de­ci­sion at every com­pa­ny with an in­ter­est in the bio­phar­ma world. Sev­er­al hun­dred have al­ready joined En­ter­prise, and now with End­points Ca­reers, we want to make it even more ben­e­fi­cial to join.

Start­ing to­day, we’re in­tro­duc­ing a new ben­e­fit for En­ter­prise sub­scribers: Two Fea­tured Job List­ings per year on End­points Ca­reers — an $800 val­ue. If you’re a hir­ing man­ag­er at a com­pa­ny with a valid En­ter­prise sub­scrip­tion, you have two fea­tured job post­ings wait­ing for you to re­deem — just con­tact Tom Kowal­sky tom@end­pointsnews.com on our team to get start­ed. And once you do, the list­ings will be dis­trib­uted across the en­tire End­points net­work: email, web, and so­cial. Again: we’re sell­ing the same pack­age for $800 for com­pa­nies who aren’t part of the En­ter­prise pro­gram.

The oth­er key ad­van­tage on End­points Ca­reers is our fo­cus on qual­i­ty, not quan­ti­ty.

Most “job boards” be­gin with thou­sands of job list­ings pre-filled, in an at­tempt to look busy and gain web traf­fic. We take the op­po­site view. We on­ly want re­cent jobs with the high­est rel­e­vance to our au­di­ence base. And giv­en the big traf­fic num­bers to End­points News and our re­lat­ed dis­tri­b­u­tion chan­nels, we’re able to ad­ver­tise these po­si­tions in a very ef­fec­tive way: Job seek­ers are as­sured of see­ing on­ly the high­est qual­i­ty list­ings from em­ploy­ers, while em­ploy­ers get wide air cov­er­age for their open po­si­tions with­in the elite End­points read­er­ship.

We de­signed it this way. Bio­phar­ma tends to be an in­su­lar crowd with an es­pe­cial­ly big pre­mi­um placed on re­fer­rals from in­side a net­work — which is no sur­prise in an in­dus­try that is as heav­i­ly reg­u­lat­ed and sci­ence-based as this one is. In­sti­tu­tion­al knowl­edge is held by peo­ple, not in com­pa­ny clouds or lab notes. And the net­work ef­fects gained from re­cruit­ing the right kind of ex­pe­ri­enced tal­ent who know the right peo­ple are too valu­able to be mea­sured in dol­lars. This won’t ever change. It’s a sto­ry we chron­i­cle in End­points about every com­pa­ny with am­bi­tion, time and time again.

But re­fer­rals do have their lim­its. Was the job op­por­tu­ni­ty ex­posed to the most di­verse tal­ent pool pos­si­ble? How does a found­ing team of a few fa­mil­iar faces re­cruit a work­force that can bring fresh ideas and ap­proach­es?

Ba­si­cal­ly: Did we cast a wide enough net?

End­points Ca­reers is here to help solve this is­sue: ad­ver­tis­ing bio­phar­ma op­por­tu­ni­ties with­in an elite net­work, and do­ing so on a scale that ex­pos­es it to the broad­est au­di­ence pos­si­ble.

We think that’s a com­pelling of­fer that con­tin­ues to dif­fer­en­ti­ate End­points and how we serve our read­ers. End­points Ca­reers will on­ly con­tin­ue to grow through­out the year as we in­te­grate it with our week­ly Peer Re­view col­umn. If you have any ques­tions or want to get start­ed with End­points Ca­reers, we’ve brought Tom tom@end­pointsnews.comon board as a ded­i­cat­ed client man­ag­er to help, and you can al­ways con­tact me di­rect­ly as well. So please check out End­points Ca­reers — we’re very ex­cit­ed to bring it to you.

– Ar­salan Arif
Founder & CEO, End­points News
aa@end­pointsnews.com

5AM Ven­tures: Fu­el­ing the Next Gen­er­a­tion of In­no­va­tors

By RBC Capital Markets
With Andy Schwab, Co-Founder and Managing Partner at 5AM Ventures

Key Points

Prescription Digital Therapeutics, cell therapy technologies, and in silico medicines will be a vital part of future treatment modalities.
Unlocking the potential of the microbiome could be the missing link to better disease diagnosis.
Growing links between academia, industry, and venture capital are spinning out more innovative biotech companies.
Biotech is now seen by investors as a growth space as well as a safe haven, fuelling the recent IPO boom.

Biohaven CEO Vlad Coric (Photo Credit: Andrew Venditti)

Pssst: That big Bio­haven Alzheimer's study? It was a bust. Even the sub­group analy­sis ex­ecs tout­ed was a flop

You know it’s bad when a biopharma player plucks out a subgroup analysis for a positive take — even though it was way off the statistical mark for success, like everything else.

So it was for Biohaven $BHVN on MLK Monday, as the biotech reported on the holiday that their Phase II/III Alzheimer’s study for troriluzole flunked both co-primary endpoints as well as a key biomarker analysis.

The drug — a revised version of the ALS drug riluzole designed to regulate glutamate — did not “statistically differentiate” from placebo on the Alzheimer’s Disease Assessment Scale-Cognitive Subscale 11 (ADAS-cog) and the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB).  The “hippocampal volume” assessment by MRI also failed to distinguish itself from placebo for all patients fitting the mild-to-moderate disease profile they had established for the study.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Hal Barron, GSK R&D chief (GSK via YouTube)

Glax­o­SmithK­line's $4B bis­pe­cif­ic can­cer drug al­liance with Mer­ck KGaA hit by set­back with a fail­ure on NSCLC

Close to 2 years ago, GSK’s R&D team eagerly agreed to pay up to $4 billion-plus to ally itself with Merck KGaA on a mid-stage bispecific called bintrafusp alfa, which intrigued them with the combination of a TGF-β trap with the anti-PD-L1 mechanism in one fusion protein.

But today the German pharma company says that their lead study on lung cancer was a bust, as independent monitors said there was no reason to believe that the experimental drug — targeting PD-L1/TGF-Beta — could beat Keytruda.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,200+ biopharma pros reading Endpoints daily — and it's free.

Bris­tol My­ers Squibb gets re­view date for Op­di­vo com­bo in gas­tric can­cer, look­ing to over­turn Keytru­da's 3-year lead

The past two months have been tough for Bristol Myers Squibb and its checkpoint inhibitor Opdivo after setbacks in lung and brain cancers. But in the battle against Merck’s Keytruda, any success matters — and now Bristol could be looking at a quick approval for Opdivo in an unmatched indication.

The FDA will launch a speedy review of a combination of Bristol Myers Squibb’s Opdivo and chemotherapy to treat first-line patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma, the drugmaker said Wednesday. The agency set an action date of May 25 for the application.

Covid-19 claims an­oth­er PDU­FA vic­tim as Glax­o­SmithK­line push­es back planned PD-1 roll­out

Bristol Myers Squibb isn’t the only pharma giant that’s been standing in the FDA’s waiting line for site inspections.

GlaxoSmithKline is telling us today that their H2 2020 PDUFA deadline for the PD-1 drug dostarlimab — picked up in its Tesaro buyout — was pushed back due to a delay in the manufacturing site inspection needed for a regulatory decision. And that is forcing the company to revise its timeline.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,200+ biopharma pros reading Endpoints daily — and it's free.

Janet Woodcock and Joshua Sharfstein (AP, Images)

Poll: Should Joshua Sharf­stein or Janet Wood­cock lead the FDA from here?

It’s time for a new FDA commissioner to come on board, a rite of passage for Joe Biden’s administration that should help seal the new president’s rep on seeking out the experts to lead the government over the next 4 years.

As of now, the competition for the top job appears to have narrowed down to 2 people: The longtime CDER chief Janet Woodcock and Joshua Sharfstein, the former principal deputy at the FDA under Peggy Hamburg. Both were appointed by Barack Obama.

Artist rendering of the Assembly Square site in Somerville, MA (BioMed Realty)

Bio­Med Re­al­ty snaps up in­no­va­tion cam­pus site with­in earshot of pricey and bustling Boston biotech hub

On the short list of the premier biotech hubs in the world, the Boston area has transformed into a home for innovation — and ridiculously high rent. Now, a real estate firm is seeking tenants for a major site in neighboring Somerville with more than enough elbow room.

Snapped up by BioMed Realty, the land — which consists of an existing 162,000 square-foot office building and a 7.5 acre site — will serve as an “innovation space” for a variety of research, technology and life science tenants, the real estate company said in a press release. Financial terms weren’t disclosed.

Sanofi protests, AP Images

Paul Hud­son faces down French unions in fight to re­struc­ture Sanofi

Sanofi CEO Paul Hudson is facing a familiar adversary in his efforts to cut up to 1,680 jobs from the French pharma giant: French unions.

Around 200 union members staged a one-day strike Tuesday at Sanofi’s main Covid-19 vaccine plant in Marcy-l’Étoile to protest the cuts, The Associated Press reported, with other members joining at other facilities across the country.

France’s finance minister Bruno Le Maire, meanwhile, went on French radio twice this week to talk about the company. On Monday, per Reuters, he told RTL that Sanofi would not close any plants or lay off any employees in the restructuring. But on Wednesday morning, he re-emerged on BFM and said he would like three things from the drugmaker, including confirmation that there will be no site closures and layoffs.

Ugur Sahin, BioNTech CEO (AP Images)

Covid-19 roundup: BioN­Tech of­fers da­ta show­ing Pfiz­er-part­nered vac­cine pro­tects against vari­ant; No­vavax at­trib­ut­es re­spon­si­bil­i­ty for PhI­II de­lay to OWS

Ugur Sahin and his team at BioNTech have proffered more evidence that their Pfizer-partnered Covid-19 vaccine can protect people from a much-feared variant of SARS-CoV-2.

Colloquially known as the UK variant, the B.1.1.7 lineage triggered alarms because it appeared more transmissible. Among a series of mutations on its spike protein — the key antigen that all frontrunners in the vaccine race targeted — N501Y was of particular concern because it’s located on the receptor-binding site.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,200+ biopharma pros reading Endpoints daily — and it's free.